文献速递淋巴瘤

来那度胺联合奥妥珠单抗及CHOP方案治疗初诊弥漫大B细胞淋巴瘤的1/2期研究

A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL.
PubMed 文献 · Blood Adv · 2023-01-01

该1b/2期研究报告53例初诊DLBCL患者接受6周期LO-CHOP方案,50例可评估者治疗结束时总缓解率98%、完全缓解率90%;中位随访4.5年,4年无进展生存率和总生存率分别为87.4%和91.3%;70%患者发生3-4级不良事件。

要点

  • 50例可评估患者治疗结束时总缓解率98%,完全缓解率90%。
  • 中位随访4.5年,4年无进展生存率87.4%,总生存率91.3%。
  • 70%患者发生3-4级不良事件,常见中性粒细胞减少(38%)。

核心结论

  • LO-CHOP方案在初诊弥漫大B细胞淋巴瘤中显示出高疗效和耐受性,并带来高比例的ctDNA检测不到微小残留病变。

研究设计与样本

  • 1b/2期研究,纳入53例初诊弥漫大B细胞淋巴瘤患者,接受6个周期LO-CHOP方案治疗。
  • 治疗方案为来那度胺联合奥妥珠单抗及CHOP(环磷酰胺、多柔比星、长春新碱、泼尼松)。
  • 试验注册号NCT02529852。

主要发现

  • 50例可评估患者治疗结束时总缓解率为98%,完全缓解率为90%。
  • 中位随访4.5年,4年无进展生存率为87.4%,4年总生存率为91.3%。
  • 70%患者发生3-4级不良事件,包括中性粒细胞减少(38%)、血小板减少(17%)、乏力(13%)和中性粒细胞减少性发热(13%)。
  • 33例患者进行循环肿瘤DNA(ctDNA)测序,其中31例(94%)治疗前可检测到ctDNA(癌症个体化深度测序分析),24例(73%)可经LymphGen分类器分类。
  • 20例中15例(75%)和17例中12例(71%)分别在1个和2个周期后达到早期和主要分子学缓解;18例可评估患者中16例(89%)在至少5个周期LO-CHOP后未检测到ctDNA(相位变异富集与检测测序)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diffuse large B-cell lymphoma (DLBCL) can be cured with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP); however, one-third of patients experience refractory or relapsed disease. Studies comparing R-CHOP with modified regimens replacing R with obinutuzumab (O) or adding lenalidomide (L) did not result in improved outcomes; however, L and O together may enhance natural killer-cell mediated antibody-dependent cellular toxicity when paired with CHOP. Here, we report on a phase 1b/2 study of 53 patients with newly diagnosed DLBCL who received 6 cycles of LO-CHOP. The end of treatment overall and complete response rates of the 50 evaluable patients were 98% and 90%, respectively. After a median follow-up of 4.5 years, the 4-year progression free and overall survival rates were 87.4% and 91.3%, respectively. Grade 3 to 4 adverse events were experienced by 70% of patients, including neutropenia (38%), thrombocytopenia (17%), fatigue (13%), and neutropenic fever (13%). Of the 33 patients profiled with circulating tumor DNA (ctDNA) sequencing, 31 (94%) had detectable pretreatment ctDNA with cancer personalized profiling by deep sequencing, 24 (73%) were classifiable by the LymphGen classifier, and 15/20 (75%) and 12/17 (71%) patients achieved early and major molecular responses after 1 and 2 cycles, respectively. Using phased variant enrichment and detection sequencing, 16/18 evaluable patients (89%) showed no detectable ctDNA after at least 5 cycles of LO-CHOP. LO-CHOP demonstrates high efficacy and tolerability in newly diagnosed DLBCL, leading to a high rate of undetectable minimal residual disease by ctDNA. This trial has been registered at www.clinicaltrials.gov as NCT02529852.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Cherng HJ, Alig SK, Oki Y, et al. A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. Blood Adv. 2023. PMID: 36375046. doi:10.1182/bloodadvances.2022008174

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。